Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Accelerating Clinical Trials in the European Union (ACT EU) Workplan 2025-2026
EU-ACT-EU-workplan-2025-2026-December-2024-1Download
Ryan McArthur 27 January 2025 All news
  • ← Committee for Medicinal Products for Human Use (CHMP): Work Plan 2025

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Accelerating Clinical Trials in the European Union (ACT EU) Workplan 2025-2026
  • Committee for Medicinal Products for Human Use (CHMP): Work Plan 2025
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025
Copyright © 2018 - Pharmya - Legal terms - Quality Policy